Stockreport

Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? [Yahoo! Finance]

Dr. Reddy's Laboratories Ltd  (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
PDF The drug remains a key top-line driver for the company. Tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, is approved by the FDA for the treatment of adult pa [Read more]